Search for: "TEVA PHARMACEUTICALS USA, INC." Results 1 - 20 of 405
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 Oct 2021, 9:50 am by Simmons Hanly Conroy
For more details on any of the previous weeks in the New York opioid trial, visit past coverage: New York Opioid Trial Begins With Opening Arguments “Gremlins” Analogy Nets National Headlines New York Agrees to $1.18 Billion Settlement With Three Major Distributors Local Officials, First Responders Testify in New York Opioid Trial New York State Files Motion for Default Judgment Endo Pharmaceuticals Agrees to Settlement Remaining defendants in the trial include Teva… [read post]
10 Aug 2021, 6:20 am by Robert Kraft
” With the “settlements, only three drug manufacturers, Endo Health Solutions, Teva Pharmaceuticals USA and Allergan Finance, remain at trial. [read post]
21 Jul 2021, 12:44 pm by Jon L. Gelman
The manufacturers named in the complaint included Purdue Pharma and its affiliates, as well as members of the Sackler Family (owners of Purdue) and trusts they control; Janssen Pharmaceuticals and its affiliates (including its parent company Johnson & Johnson); Mallinckrodt LLC and its affiliates; Endo Health Solutions and its affiliates; Teva Pharmaceuticals USA, Inc. and its affiliates; and Allergan Finance, LLC and its affiliates. [read post]
30 Apr 2021, 8:07 am by Dan Bressler
Barclay Surrick to require Morgan Lewis to answer a series of questions about its ability to ethically represent Glenmark Pharmaceuticals Inc. [read post]
2 Nov 2020, 1:41 pm by Courtenay C. Brinckerhoff
Teva Pharmaceuticals USA, Inc., is getting attention for potentially “endangering” the practice of skinny labelling. [read post]
8 Oct 2020, 9:59 pm by Patent Docs
What Quantum of Culpable Conduct Is Required for an ANDA Applicant to Induce Infringement? [read post]
5 Oct 2020, 1:15 pm by Rebecca Tapscott
Teva Pharmaceuticals USA, Inc., the United States Court of Appeals for the Federal Circuit (CAFC) on Friday reversed a district court’s motion for judgment as a matter of law (JMOL) for Teva, finding that Teva was liable for induced infringement of GlaxoSmithKline's (GSK’s) patent directed to a method of treating Congestive Heart Failure (CHF) using carvedilol..... [read post]
5 Oct 2020, 1:15 pm by Rebecca Tapscott
Teva Pharmaceuticals USA, Inc., the United States Court of Appeals for the Federal Circuit (CAFC) on Friday reversed a district court’s motion for judgment as a matter of law (JMOL) for Teva, finding that Teva was liable for induced infringement of GlaxoSmithKline's (GSK’s) patent directed to a method of treating Congestive Heart Failure (CHF) using carvedilol..... [read post]
11 Sep 2020, 7:06 am by Peter Briccetti
The U.S. government filed a False Claims Act case against Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. [read post]
30 Aug 2020, 10:19 am by Ben Vernia
According to DOJ’s press release: The United States has filed a False Claims Act complaint against Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. [read post]
13 Aug 2020, 9:59 pm by Patent Docs
Teva Pharmaceuticals USA, Inc., affirmed a District Court's finding that the asserted claims to a pharmaceutical formulation were indefinite. [read post]
14 Jul 2020, 5:00 am by Carolyn Casey, J.D.
The makers named in the recall are Apotex Corp., Amneal Pharmaceuticals, Marksans Pharma Limited’s Time-Cap Labs, Inc., Lupin Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc. [read post]
17 Mar 2020, 1:32 pm by Noble McIntyre
One Lot of Topotecan Injection 4 mg/4 mL (1 mg/mL) has been recalled by Teva Pharmaceuticals due to the presence of particulate matter. [read post]
25 Feb 2020, 2:10 am by Courtenay C. Brinckerhoff
Teva Pharmaceuticals USA, Inc., is a non-precedential decision that was issued on the briefs (without oral argument), but is worth reviewing for its discussion of anticipation and inherency in the context of method of treatment claims. [read post]
4 Feb 2020, 5:00 am by Jason Rantanen
Teva Pharmaceuticals USA, Inc., the Supreme Court, in its first case addressing the AIA’s § 102, rejected this argument. [read post]